51 related articles for article (PubMed ID: 2644395)
1. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
2. Headache in COVID-19 and Long COVID: to Know Facts for Clinical Practice.
Gómez-Dabó L; Melgarejo-Martínez L; Caronna E; Pozo-Rosich P
Curr Neurol Neurosci Rep; 2023 Oct; 23(10):551-560. PubMed ID: 37665495
[TBL] [Abstract][Full Text] [Related]
3. A Review on Headaches Due to COVID-19 Infection.
Togha M; Hashemi SM; Yamani N; Martami F; Salami Z
Front Neurol; 2022; 13():942956. PubMed ID: 35911910
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.
Grant SM; Heel RC
Drugs; 1992 Apr; 43(4):516-560. PubMed ID: 28421558
[TBL] [Abstract][Full Text] [Related]
5. A comparative review of colony-stimulating factors.
Nemunaitis J
Drugs; 1997 Nov; 54(5):709-29. PubMed ID: 9360058
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
Ragnhammar P
Med Oncol; 1996 Sep; 13(3):167-76. PubMed ID: 9106176
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
Riccardi A; Danova M; Paccagnella A; Giordano M; Favaretto A; Panozzo M; Ghiotto C; Comis S; Fiorentino M; Chieco-Bianchi L
Ann Hematol; 1993 Apr; 66(4):185-93. PubMed ID: 8387346
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
Eguchi K; Kabe J; Kudo S; Mano K; Morinari H; Nakada K; Noda K; Saito Y; Tanaka T; Uzawa T
Cancer Chemother Pharmacol; 1994; 34(1):37-43. PubMed ID: 8174201
[TBL] [Abstract][Full Text] [Related]
10. High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
Ferguson JE; Dodwell DJ; Seymour AM; Richards MA; Howell A
Br J Cancer; 1993 Apr; 67(4):825-9. PubMed ID: 7682432
[TBL] [Abstract][Full Text] [Related]
11. Marker gene transfer into leukapheresis preparations containing hematopoietic progenitor cells: application in high-dose therapy rescued by reinfusion of peripheral blood hematopoietic progenitors in patients with multiple myeloma.
Herrmann F; Kiehntopf M; Brach MA; Carstanjen D; von Schilling C
J Mol Med (Berl); 1995 Apr; 73(4):197-203. PubMed ID: 7627640
[No Abstract] [Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
[TBL] [Abstract][Full Text] [Related]
13. Polypeptides controlling hematopoietic blood cell development and activation. II. Clinical results.
Herrmann F; Lindemann A; Mertelsmann R
Blut; 1989 Apr; 58(4):173-9. PubMed ID: 2650757
[TBL] [Abstract][Full Text] [Related]
14. G-CSF and GM-CSF in clinical trials.
Antman KH
Yale J Biol Med; 1990; 63(5):387-410. PubMed ID: 1705737
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytokines on growth in vitro of primary human renal cell carcinoma.
de Riese W; Allhoff EP; Werner M; Stief CG; Liedke S; Kirchner H; Atzpodien J
Urol Res; 1992; 20(5):369-73. PubMed ID: 1280874
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
J Clin Oncol; 1989 Feb; 7(2):159-67. PubMed ID: 2644395
[TBL] [Abstract][Full Text] [Related]
17. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
